New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
10:14 EDTALNY, TS, LUFK, ESV, BAS, BHI, LNKD, NR, AMGN, KEY, GMCR, KMB, SCHW, FOSL, ELN, PDCE, PMC, POWI, PRI, SIAL, S, CMAOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Alnylam (ALNY) downgraded to Hold from Buy at MLV Equity... Charles Schwab (SCHW) downgraded to Sell from Neutral at Citigroup... Elan (ELN) downgraded to Neutral from Buy at UBS... Fossil (FOSL) downgraded to Hold from Buy at Benchmark Co... PDC Energy (PDCE) downgraded to Neutral from Buy at SunTrust... PharMerica (PMC) downgraded to Sector Perform from Outperform at RBC Capital... Power Integrations (POWI) downgraded to Hold from Buy at Deutsche Bank... Primerica (PRI) downgraded to Market Perform from Outperform at Keefe Bruyette... Sigma-Aldrich (SIAL) downgraded to Sell from Neutral at UBS... Sprint (S) downgraded to Neutral from Overweight at Atlantic Equities... Kimberly Clark (KMB) downgraded to Underweight from Equal Weight at Barclays... Green Mountain (GMCR) downgraded to Neutral from Buy at Dougherty... Tenaris (TS) downgraded to Hold from Buy at Dahlman Rose... Lufkin (LUFK) downgraded to Hold from Buy at Dahlman Rose... Ensco (ESV) downgraded to Hold from Buy at Dahlman Rose... Basic Energy (BAS) downgraded to Hold from Buy at Dahlman Rose... Baker Hughes (BHI) downgraded to Hold from Buy at Dahlman Rose... LinkedIn (LNKD) downgraded to Market Perform from Outperform at Northland Securities... Newpark Resources (NR) downgraded to Hold from Buy at Dahlman Rose... Amgen (AMGN) downgraded to Market Perform from Outperform at William Blair... KeyCorp (KEY) downgraded at Stifel Nicolaus... Comerica (CMA) downgraded at Stifel Nicolaus.
News For ALNY;SCHW;FOSL;ELN;PDCE;PMC;POWI;PRI;SIAL;S;KMB;GMCR;TS;LUFK;ESV;BAS;BHI;LNKD;NR;AMGN;KEY;CMA From The Last 14 Days
Check below for free stories on ALNY;SCHW;FOSL;ELN;PDCE;PMC;POWI;PRI;SIAL;S;KMB;GMCR;TS;LUFK;ESV;BAS;BHI;LNKD;NR;AMGN;KEY;CMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 20, 2014
08:43 EDTPOWIInfineon 'not commenting on rumors,' seeking acquisitions, Reuters reports
Subscribe for More Information
08:42 EDTPOWIInfineon nears deal to buy U.S. semi company for $2B, Bloomberg reports
Subscribe for More Information
08:07 EDTALNYAlnylam receives USPTO notice of allowance for new patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” amongst other naturally or non-naturally occurring nucleotide analogues. The allowed claims of the Tuschl ’262 patent application, as well as other granted, Alnylam-owned or -licensed patents, in aggregate broadly cover compositions, methods, and uses of RNAi therapeutics.
08:01 EDTLNKDAd spending on LinkedIn reportedly rising, says Pacific Crest
Subscribe for More Information
07:01 EDTPOWIInfineon near deal to buy U.S. semi company for $2B, Bloomberg says
Subscribe for More Information
August 19, 2014
15:54 EDTPDCEEnerCom to hold a conference
Subscribe for More Information
15:50 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
12:42 EDTSOn The Fly: Midday Wrap
The market opened higher as it extended its gains from yesterday. Better than expected economic data on housing and consumer prices, as well as easing geopolitical tensions, has helped aid investor optimism. The market drifted higher throughout the morning with the Dow leading the way, followed by the Nasdaq, which is now near fourteen-year highs. The S&P is mostly higher, with the telecom services group being the lone sector showing losses, down just fractionally. ECONOMIC EVENTS: Housing starts for July rose to an annualized pace of 1.093M units, up from 0.945M units in June, and beating expectations for 0.963M units... The Consumer Price Index increased 0.1% overall, matching expectations. Less food and energy, the CPI was up 0.1%, which was also in-line with the consensus forecast. COMPANY NEWS: Shares of home improvement retailer The Home Depot (HD) are up more than 6% after the company posted better than expected second quarter results and raised its full year profit outlook... Shares of Sprint (S) are down 4% after Jefferies lowered its price target for Sprint shares to $4, saying it continues to see downside to estimates. MAJOR MOVERS: Shares of Skilled Healthcare (SKH) are up more than 20% after combining with Genesis HealthCare In 100% stock deal... Shares of cosmetics and fragrance company Elizabeth Arden (RDEN) are down 24% after the company's fourth quarter results came in well below analysts' consensus estimates. INDEXES: Near midday, the Dow was up 76.92, or 0.46%, to 16,915.66, the Nasdaq was up 12.96, or 0.29%, to 4,521.27, and the S&P 500 was up 8.49, or 0.43%, to 1,980.23.
10:32 EDTLNKDRumor: LinkedIn moves lower on speculation of a large investor short position
09:01 EDTGMCRKeurig Green Mountain estimates raised at SunTrust
Subscribe for More Information
07:39 EDTSSprint price target lowered to $4 from $7 at Jefferies
Jefferies lowered its price target for Sprint shares to $4 saying it continues to see downside to estimates. The firm expects a "muted response" to Sprint's new Family Pack pooled data plan and limited time promotion of waiving device access charges. It keeps an Underperform rating on the stock.
07:18 EDTBASEnerCom to hold a conference
Subscribe for More Information
07:12 EDTSFCC looks into telecom special access line rates, Reuters says
Subscribe for More Information
05:11 EDTAMGNGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
19:41 EDTSSprint CEO says regulators weren't set on industry consolidation, Bloomberg says
Sprint (S) recently dropped its bid seeking control of competitor T-Mobile (TMUS).
18:33 EDTSSprint introduces Sprint Family Share Pack data plan, doubles high-speed data
Subscribe for More Information
18:04 EDTSSprint to offer $100/month 20GB shared data plan through 2015, Bloomberg reports
Subscribe for More Information
17:25 EDTAMGNAmgen announces AMG 416 study met its primary and all secondary endpoints
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism, SHPT, in patients with chronic kidney disease,CKD, receiving hemodialysis, met its primary and all secondary endpoints. "The results from this second Phase 3 study help to confirm that AMG 416 could become an important new treatment option for dialysis patients with secondary hyperparathyroidism," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Despite the variety of options available for the treatment of this disease, an unmet need remains for an intravenous therapy that can be administered along with hemodialysis. We look forward to sharing results of a head-to-head study evaluating AMG 416 compared to cinacalcet next year."
11:06 EDTSSoftBank chooses Sharp as low-cost smartphone partner, WSJ reports
Subscribe for More Information
08:47 EDTSRaymond James to hold a summit
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use